ストックスクリーナーアプリを入手
13.14
0.69%
0.09
前日終値:
$13.05
開ける：
$13.05
24時間の取引高:
97,950
Relative Volume:
1.05
時価総額：
$451.02M
収益：
$99.53M
当期純損益:
$-21.57M
株価収益率:
-20.25
EPS:
-0.6488
ネットキャッシュフロー:
$-9.84M
1週間 パフォーマンス:
+2.82%
1か月 パフォーマンス:
-10.67%
6か月 パフォーマンス:
-22.61%
1年 パフォーマンス:
+21.22%
1日の値動き範囲:
$12.92
$13.43
1週間の範囲:
$12.16
$13.69
52週間の値動き範囲:
$9.22
$19.60
Neuropace Inc Stock (NPCE) Company Profile
Compare NPCE vs ABT, MDT, SYK, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
13.14 | 451.02M | 99.53M | -21.57M | -9.84M | -0.6488 |
ABT
Abbott Laboratories
|
102.51 | 177.38B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
96.59 | 123.55B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
307.08 | 117.79B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
46.01 | 66.68B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.09 | 51.93B | 6.30B | 1.07B | 1.09B | 1.8406 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-09-18 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2026-07-23 | 開始されました | Mizuho | Outperform |
| 2025-05-28 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-21 | 開始されました | UBS | Buy |
| 2024-03-14 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | 開始されました | Leerink Partners | Outperform |
| 2023-11-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-08-24 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | 開始されました | Lake Street | Buy |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-01-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | 開始されました | Robert W. Baird | Outperform |
| 2021-05-17 | 開始されました | JP Morgan | Overweight |
| 2021-05-17 | 開始されました | Morgan Stanley | Overweight |
| 2021-05-17 | 開始されました | SVB Leerink | Outperform |
| 2021-05-17 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Neuropace Inc (NPCE) 最新ニュース
Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight - GlobeNewswire Inc.
After shares were withheld for taxes, NeuroPace (NPCE) medical chief Martha Morrell held 51,357 shares. - Stock Titan
NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Form 4 Neuropace Inc For: 22 September By Investing.com - Investing.com Canada
Form 4 Neuropace Inc For: 22 September By Investing.com - Investing.com Nigeria
Form 4 Neuropace Inc For: 22 September - Investing.com India
NeuroPace CFO Patrick Williams Discloses Tax-Related Share Withholding on RSU Vesting - kalkinemedia.com
NeuroPace (NPCE) CFO has 1,162 shares withheld for taxes - Stock Titan
Precision Trading with Neuropace Inc. (NPCE) Risk Zones - Stock Traders Daily
Bank of America Corp DE Sells 145,741 Shares of NeuroPace, Inc. $NPCE - MarketBeat
First Light Asset Management, LLC Adds 1.34 Million NeuroPace In - GuruFocus
Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report? - Yahoo Finance
First Light Asset Management LLC Boosts Stake in NeuroPace, Inc. $NPCE - MarketBeat
NeuroPace Inc. (NPCE) Eases 1.76% to $14.50 as Shares Sit Mid-Range Between Support and ResistanceVolume Gap - siam.in
NeuroPace at Cantor healthcare conference: growth, data and FDA path By Investing.com - Investing.com India
NeuroPace at Cantor healthcare conference: growth, data and FDA path By Investing.com - Investing.com Canada
NeuroPace at Cantor healthcare conference: growth, data and FDA path By Investing.com - Investing.com UK
NeuroPace at Wells Fargo conference: IGE push faces FDA test By Investing.com - Investing.com Canada
NeuroPace at Wells Fargo conference: IGE push faces FDA test By Investing.com - Investing.com India
NPCE: Strong clinical data and regulatory progress position the RNS system for significant growth in epilepsy care - tradingview.com
NeuroPace at Wells Fargo conference: IGE push faces FDA test - Investing.com
NeuroPace (NPCE) CEO uses 1,310 shares to cover taxes - Stock Titan
Over 12% of NeuroPace (NPCE) may be owned by one investor - Stock Titan
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now - Yahoo Finance
Man Group plc Makes New $1.34 Million Investment in NeuroPace, Inc. $NPCE - MarketBeat
2,477,603 Shares in NeuroPace, Inc. $NPCE Bought by BlackRock Inc. - MarketBeat
Precision Trading with Neuropace Inc. (NPCE) Risk Zones - Stock Traders Daily
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference - marketscreener.com
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference - Business Wire
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference - Business Wire
Wells Fargo conference to feature NeuroPace fireside chat Sept. 8 - Stock Titan
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
NeuroPace (NPCE) CEO settles RSU tax bill with 1,126 shares - Stock Titan
NeuroPace (NASDAQ: NPCE) CMO has 358 shares withheld for taxes - Stock Titan
NeuroPace Inc (NPCE) Stock Up 3.8% but GF Value Says Overvalued -- GF Score: 70/100 - GuruFocus
Neuropace (NPCE) Results Check: EPS Lands Above Forecast; Share Move: Shares Finish 1.22% Up on the DayGeographic Revenue Trends - dars.gov.et
Deutsche Bank AG Acquires Shares of 938,919 NeuroPace, Inc. $NPCE - MarketBeat
Neuropace (NPCE) Stock: Ends Up by 0.07% at $14.03; Technical Setup: the $13.33 to $14.73 Range Remains in Focus at the CloseMFI Oversold - vinanet.vn
Neuropace (NPCE) Stock: Ends Up by 0.07% at $14.03; Technical Setup: the $13.33 to $14.73 Range Remains in Focus at the CloseNHNL Ratio - dars.gov.et
Neuropace (NPCE) Market: Posts a 0.07% Gain to $14.03 in the Current Update; Technical View: the $13.33 to $14.73 Range Remains in Focus in Latest TradingPassive Flow - vinanet.vn
HC Wainwright Has Positive Outlook of NeuroPace Q3 Earnings - MarketBeat
HC Wainwright Brokers Lower Earnings Estimates for NeuroPace - MarketBeat
Neuropace (NPCE) Close in Focus: Finishes 1.33% Higher at $14.47 at the Close; Technical Focus: the Price Remains Bounded by the Supplied Support and Resistance on the DayTrend Following Picks - vinanet.vn
Neuropace (NPCE) Close in Focus: Finishes 1.33% Higher at $14.47 at the Close; Technical Focus: the Price Remains Bounded by the Supplied Support and Resistance on the DayWave Equality - dars.gov.et
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth - Zacks Investment Research
Neuropace (NPCE) Close in Focus: Finishes 1.33% Higher at $14.47 at the Close; Technical Focus: the Price Remains Bounded by the Supplied Support and Resistance on the DayQuality ETF - dars.gov.et
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth - Zacks Investment Research
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth - Yahoo Finance
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated? - Yahoo Finance
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity? - Yahoo Finance
Neuropace Inc (NPCE) 財務データ
収益
当期純利益
現金流量
EPS
Neuropace Inc (NPCE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MARTHA J MORRELL | Officer |
Dec 15 '25 |
Proposed Sale |
16.19 |
25,000 |
404,750 |
0 |
4.51%
0.85%
大文字化:
|
ボリューム (24 時間):